FDA OK's CSL Behring's Kcentra in surgery use
This article was originally published in Scrip
Executive Summary
The US FDA on 13 December expanded the labeling for CSL Behring's drug Kcentra (prothrombin complex concentrate [human]) to include urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonists like warfarin therapy in adults needing an urgent surgery or other invasive procedure.